New shot could help diabetics lose weight and lower blood sugar

NCT ID NCT05110846

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new daily injection called CT-868 in 103 overweight or obese adults with type 2 diabetes. Participants received either the drug or a placebo for 26 weeks. The main goal was to see if CT-868 could lower blood sugar levels (HbA1c) and help with weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CT-868 (a once-daily injection)
What this could lead to
If successful, this could point toward a new daily injection that helps control blood sugar and reduce weight in people with type 2 diabetes.
What could go wrong
This is a Phase 2 trial with only 103 participants, so results may not apply to everyone. The drug is still experimental and may not prove better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Carmot Clinical Center MX01

    Monterrey, Nuevo León, Mexico

  • Carmot Clinical Center MX02

    Monterrey, Nuevo León, Mexico

  • Carmot Clinical Center MX03

    Mexico City, Mexico

  • Carmot Clinical Center MX04

    Guadalajara, Jalisco, Mexico

  • Carmot Clinical Center MX05

    Mérida, Yucatán, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.